Table 2 of
Cehofski, Mol Vis 2024; 30:17-35. Table 2 of
Cehofski, Mol Vis 2024; 30:17-35.
Table 2. Samples for validation by ELISA.
| Various | DME ELISA | Control | P-value |
|---|---|---|---|
| Number of samples | 15 | 8 | |
| Patients | 15 | 7 | |
| Age (years) | 65.2±15.1 | 71.0±9.3 | 0.32 |
| Sex (M/F) | 9/6 | 4/4 | |
| BCVA (logMAR) | 0.44±0.28 | ||
| Central subfield thickness (µm) | 384.5±161.9 | ||
| Mild non-proliferative diabetic retinopathy (n) | 2 | ||
| Moderate non-proliferative diabetic retinopathy (n) | 4 | ||
| Severe non-proliferative diabetic retinopathy (n) | 4 | ||
| Proliferative diabetic retinopathy (n) | 5 | ||
| HbA1c (%) | 7.9±1.82 | ||
| Hypertension (n) | 10 | 3 | 0.22 |
| Hyperlipidemia (n) | 5 | 0 | 0.12 |
| Oral treatment (n) | 14 | ||
| Oral treatment and insulin (n) | 4 | ||
| Insulin, no oral treatment (n) | 0 | ||
| Creatinin (mg/dl) | 1.31±0.95 | 0.82±0.12 | 0.11 |